Medi Caps Ltd.
NSE: MEDICAPQ · Pharmaceuticals · sector
₹24.44NSE close 2026-10-26
Key numbers
Market cap₹30 cr
Price₹24.44
52w high / low₹37 / ₹20
P/E3.9xSector median 27.9x
P/B0.3xSector median 2.9x
Book value₹89.5
Dividend yield–Sector median 0.48%
ROE-1.5%Sector median 11.7%
ROCE-1.6%Sector median 12.3%
OPM-62.7%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover–
Current ratio17.34x
Sales growth 3y+399.3%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.03x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹24 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Net loss in 4 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹24.44 on 2026-10-26: -33.6% from the 52-week high, +20.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹54.19 · low ₹22.09
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 7 | 3 | 2 | 4 | 3 | 3 |
| EBITDA | -0 | -3 | -3 | -1 | -2 | -2 |
| OPM % | -3.2% | -125.7% | -144.8% | -24.7% | -59.7% | -65.6% |
| Other income | 2 | 0 | 2 | 1 | 6 | 0 |
| Net profit | 2 | -3 | -2 | -1 | 3 | -2 |
| EPS (₹) | 1.38 | 2.80 | 1.46 | 0.61 | 2.44 | 1.79 |
| Revenue YoY | -50.4% | +3.7% | ||||
| Profit YoY | +76.7% | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | – | 0 | 7 | 25 | 12 | 13 |
| EBITDA | -1 | -0 | 5 | -2 | -9 | -8 |
| Net profit | -0 | 0 | 4 | -1 | -3 | -2 |
| EPS (₹) | -0.06 | 0.21 | 3.12 | 0.46 | 2.44 | 6.30 |
| Revenue growth | – | +7,070.0% | +255.4% | -51.1% | – | |
| Profit growth | – | +2,493.3% | -114.7% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +399.3% | – | – |
| Net profit | – | – | – |
| EPS | +126.5% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 121 | 112 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 29 | 24 |
| Total assets | 125 | 115 |
| Fixed assets | 28 | 27 |
| Capital work in progress | 0 | 0 |
| Investments | 15 | 12 |
| Receivables | 9 | 7 |
| Inventory | 3 | 3 |
| Payables | 2 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 5 | -7 |
| Cash from investing | -5 | 7 |
| Cash from financing | 0 | 0 |
| Capex | 0 | 1 |
| Free cash flow | 5 | -8 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -0.5% | -2.7% |
| ROCE % | -0.7% | -2.7% |
| Debtor days | 126 | 203 |
| Inventory days | 110 | 190 |
| Payable days | 54 | 31 |
| Cash conversion cycle (days) | 182 | 362 |
| Working capital days | 721 | 1,299 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MEDICAPQ | ₹30 cr | 3.9x | 0.3x | -1.5% | -1.6% | -62.7% | +399.3% | – |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Pharma Devision | ₹3 cr | 96.2% | ₹-2 cr | -61.3% |
| Real Estate Devision | ₹0 cr | 3.8% | ₹-1 cr | -562.1% |
| Other | ₹0 cr | – | ₹0 cr | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2012-09-20 | Dividend | Dividend Rs 1.5 |
| 2011-09-22 | Dividend | Dividend Rs 1.5 |
| 2010-09-22 | Dividend | Dividend Rs 1.5 |
| 2009-09-24 | Dividend | Dividend Rs 1.5 |
| 2008-09-24 | Dividend | Dividend Rs 1.5 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MEDICAPQ |
| BSE code | 523144 |
| ISIN | INE442D01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.